At the same time, RYZUMVITM-an FDA-approved, revenue-generating product partnered with Viatris Inc.-has been quietly sidelined. RYZUMVITM eye drops remain a commercially promising asset with potential relevance for two large chronic indications: presbyopia and night vision disturbance. Under the terms of the Viatris partnership, the Company is not expected to incur additional development costs related to these programs. However, since 2023, there has been no clear update regarding international expansion, commercial investment, or progress on the broader development strategy. This lack of transparency is particularly troubling given that RYZUMVITM could generate up to $20 million in milestone payments in 2026 and provide double-digit royalties through 2040, without the same development and regulatory risks that characterize the Company's early-stage gene therapy pipeline.